

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

TERMINATION OF CONTINUING CONNECTED TRANSACTION

TERMINATION OF CONTINUING CONNECTED TRANSACTION

Reference is made to the Prospectus in relation to, among other things, the General Service Framework Agreement entered into between the Company and WXAT Shanghai in relation to the provision of utilities billing services.

Since the Listing, the Company has successfully established its own independent functions in various aspects, including its utilities accounts in the buildings it use, which can now be separated from WXAT Shanghai's utilities accounts. As the Company has established its own utilities accounts and paid for its own utilities bill and hence, it is no longer necessary to obtain such utilities billing services from WXAT Shanghai.

On August 23, 2018, the Company and WXAT Shanghai entered into a termination agreement pursuant to which both parties have agreed to terminate the General Service Framework Agreement, with immediate effect, and confirmed none of the parties shall have any claim against the others arising from the termination.

LISTING RULES IMPLICATIONS

As the Founding Individuals, who are the controlling shareholders of the Company, have controlled more than 30% voting power in WuXi AppTec, WuXi AppTec is regarded as an associate of the Founding Individuals and hence a connected person of the Company. Accordingly, WXAT Shanghai is also a connected person of the Company by virtue of being a wholly-owned subsidiary of WuXi AppTec. Therefore, the General Service Framework Agreement and the transactions contemplated thereunder were continuing connected transactions of the Company under Chapter 14A of the Listing Rules. The termination of the General Service Framework Agreement is subject to the announcement requirement pursuant to Rule 14A.35 of the Listing Rules.

Reference is made to the Prospectus in relation to, among other things, the General Service Framework Agreement entered into between the Company and WXAT Shanghai in relation to the provision of utilities billing services.

TERMINATION OF CONTINUING CONNECTED TRANSACTION

On August 23, 2018, the Company and WXAT Shanghai entered into the Termination Agreement pursuant to which both parties have agreed to terminate the General Service Framework Agreement, with immediate effect, and confirmed none of the parties shall have any claim against the others arising from the termination.

REASONS FOR ENTERING INTO THE TERMINATION AGREEMENT

Since the Listing, the Company has successfully established its own independent functions in various aspects, including its utilities accounts in the buildings it use, which can now be separated from WXAT Shanghai's utilities accounts. As the Company has established its own utilities accounts and paid for its own utilities bill and hence, it is no longer necessary to obtain such utilities billing services from WXAT Shanghai.

In light of the aforesaid, the Company and WXAT Shanghai, after undergoing good faith discussion with each other, have agreed to terminate the General Service Framework Agreement.

The Directors are of the view that entering into the Termination Agreement will not cause any material adverse impact to the Group's business and operational activities. In addition, the Directors (including the independent non-executive Directors) consider that the Termination Agreement has been negotiated on an arm's length basis, entered into in the ordinary and usual course of business of the Company and are on normal commercial terms or better, which are fair and reasonable, and in the interests of the Company and its Shareholders as a whole.

INFORMATION ON THE GROUP AND WXAT SHANGHAI

The Group

The Group is principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry in both the PRC and other overseas countries.

WXAT Shanghai

WXAT Shanghai is a wholly-owned subsidiary of WuXi AppTec and therefore a connected person of the Company. Its principal business is the development of chemical synthesis.

LISTING RULES IMPLICATIONS

As the Founding Individuals, who are the controlling shareholders of the Company, have controlled more than 30% voting power in WuXi AppTec, WuXi AppTec is regarded as an associate of the Founding Individuals and hence a connected person of the Company. Accordingly, WXAT Shanghai is also a connected person of the Company by virtue of being a wholly-owned subsidiary of WuXi AppTec. Therefore, the General Service Framework Agreement and the transactions contemplated thereunder were continuing connected transactions of the Company under Chapter 14A of the Listing Rules. The termination of the General Service Framework Agreement is subject to the announcement requirement pursuant to Rule 14A.35 of the Listing Rules.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:

“associate”	has the meaning ascribed to it in the Listing Rules
“Board”	the board of directors of the Company
“Company”	WuXi Biologics (Cayman) Inc. (藥明生物技術有限公司*), a company incorporated in the Cayman Islands with limited liability, whose Shares are listed on The Stock Exchange of Hong Kong Limited
“connected person(s)”	has the meaning ascribed to it in the Listing Rules
“Director(s)”	director(s) of the Company
“Founding Individuals”	Dr. Ge Li, Dr. Ning Zhao, Mr. Xiaozhong Liu and Mr. Zhaohui Zhang
“General Service Framework Agreement”	the general service framework agreement dated May 17, 2017 entered into between the Company and WXAT Shanghai
“Group”	the Company and its subsidiaries from time to time
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing”	the listing of the Shares on the Main Board of The Stock Exchange of Hong Kong Limited on June 13, 2017
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China (for the purpose of this announcement, excluding Hong Kong, the Macao Special Administrative Region of the PRC and Taiwan)
“Prospectus”	the prospectus issued by the Company dated May 31, 2017
“Shares”	ordinary share(s) in the capital of the Company with nominal value of US\$0.000025 each

“Shareholder(s)”	holder(s) of Shares
“Termination Agreement”	the termination agreement dated August 23, 2018 entered into between the Company and WXAT Shanghai in relation to termination of the General Service Framework Agreement
“WuXi AppTec”	WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司), a company incorporated in the PRC on December 1, 2000 and the shares of which are listed on Shanghai Stock Exchange (Stock code: 603259), in which the Founding Individuals own more than 30% of its voting power
“WXAT Shanghai”	WuXi AppTec (Shanghai) Co., Ltd. (上海藥明康德新藥開發有限公司), a company incorporated in the PRC on April 2, 2002 and a wholly-owned subsidiary of WuXi AppTec
“%”	per cent

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, August 23, 2018

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

* *For identification purpose only*